Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 5 » Supplement 1

Use of ipilimumab in the treatment of melanoma

Authors Acharya UH, Jeter JM

Received 5 April 2013

Accepted for publication 28 May 2013

Published 9 August 2013 Volume 2013:5(Supplement 1) Pages 21—27

DOI https://doi.org/10.2147/CPAA.S45884

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4


Utkarsh H Acharya, Joanne M Jeter

Department of Medicine, Division of Hematology-Oncology, University of Arizona Cancer Center, Tucson, AZ, USA

Abstract: Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been approved by the US Food and Drug Administration for the treatment of metastatic melanoma. Phase III trials have demonstrated an overall survival benefit with its use when compared with standard treatments and other investigational therapies. However, the drug poses a notable challenge, given its propensity for toxicity, and requires close surveillance when administered in clinical practice. This review discusses the mechanism of action for ipilimumab, its preclinical data, and the clinical trials that led to its approval by the Food and Drug Administration in 2011.

Keywords: melanoma, immunotherapy, ipilimumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]